157 related articles for article (PubMed ID: 24029310)
1. Re: Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Taneja SS
J Urol; 2013 Oct; 190(4):1246. PubMed ID: 24029310
[No Abstract] [Full Text] [Related]
2. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
3. Testosterone therapy and prostate cancer--safety concerns are well founded.
Klotz L
Nat Rev Urol; 2015 Jan; 12(1):48-54. PubMed ID: 25563848
[TBL] [Abstract][Full Text] [Related]
4. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
Meza J; Weaver K; Martin S
Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
[No Abstract] [Full Text] [Related]
5. Clinical inquiries. How should we monitor men receiving testosterone replacement therapy?
Alsina M; St Anna L
J Fam Pract; 2010 Dec; 59(12):711-2. PubMed ID: 21135929
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.
Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609
[TBL] [Abstract][Full Text] [Related]
8. Malignant medication? Testosterone and cancer.
Pastuszak AW
BJU Int; 2015 Feb; 115(2):179-80. PubMed ID: 25604717
[No Abstract] [Full Text] [Related]
9. Monitoring androgen replacement therapy: testosterone and prostate safety.
Morales A
J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
[TBL] [Abstract][Full Text] [Related]
10. Testosterone therapy: has overuse undermined use?
The Lancet Diabetes Endocrinology
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):157. PubMed ID: 29475492
[No Abstract] [Full Text] [Related]
11. [Risks, contraindications, abuse and monitoring risks of testosterone replacement therapy (TRT)].
Glina S; Wroclawski ER; Chaves OH
Int Braz J Urol; 2006; 32 Suppl 1():31-4. PubMed ID: 23631039
[No Abstract] [Full Text] [Related]
12. Of fires and frying pans.
Roth RB; Hess E; Kaminsky AF
JAMA; 2015 Feb; 313(6):632. PubMed ID: 25668278
[No Abstract] [Full Text] [Related]
13. Editor's Comment--How Dangerous is Testosterone Supplementation?
Jenkins LC; Mulhall JP
Int Braz J Urol; 2015; 41(2):195-8. PubMed ID: 26005958
[No Abstract] [Full Text] [Related]
14. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.
Kim JW
Investig Clin Urol; 2020 May; 61(3):242-249. PubMed ID: 32377599
[TBL] [Abstract][Full Text] [Related]
15. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
Klap J; Schmid M; Loughlin KR
J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
[TBL] [Abstract][Full Text] [Related]
16. [Androgen replacement therapy and prostate cancer].
Beuzeboc P; Richaud P
Prog Urol; 2003 Nov; 13(5 Suppl 2):1276-7. PubMed ID: 15816405
[No Abstract] [Full Text] [Related]
17. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
18. Re: Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
Seftel AD
J Urol; 2015 Jun; 193(6):1985-6. PubMed ID: 25986797
[No Abstract] [Full Text] [Related]
19. [Abdominal pain and hypertension in a 55-year-old male patient].
Kofler T; Yueksel F; Dirnhofer S; Donath MY; Trendelenburg M
Internist (Berl); 2017 Apr; 58(4):397-401. PubMed ID: 28005140
[TBL] [Abstract][Full Text] [Related]
20. Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
Barqawi AB; Crawford ED
J Urol; 2006 Apr; 175(4):1572-3; author reply 1573-4. PubMed ID: 16552901
[No Abstract] [Full Text] [Related]
[Next] [New Search]
